Literature DB >> 16972761

Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses.

Manel Cascallo1, Alena Gros, Neus Bayo, Teresa Serrano, Gabriel Capella, Ramon Alemany.   

Abstract

Deletion of viral functions that can be complemented by the specific phenotype of tumor cells is a common strategy to design oncolytic viruses. For example, enhanced mRNA cytoplasmic export in tumor cells phenocopies the adenovirus E1B-55K function and renders mutants of this protein tumor selective. Also, an activated RB pathway complements specific E1A functions that can be deleted to produce oncolytic viruses. In this paper we demonstrate that an adenoviral mutant deleted in virus-associated I (VAI) and VAII RNAs (Ad-VAdel) has oncotropism characterized by 100-fold replication deficiency compared with wild-type adenovirus in normal cells and an unaffected ability to replicate and kill different types of tumor cells. This mutant also displays active antitumoral activity in vivo. In contrast, this oncotropism is less evident in a mutant expressing an inactive form of VAI (Adsub719) because VAII RNA expression is upregulated. The mRNA translation promoted by VA RNA genes can be phenocopied in tumor cells with the activation of signal transduction pathways, such as the Ras pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972761     DOI: 10.1089/hum.2006.17.929

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  14 in total

1.  HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Authors:  Sylvanne M Daniels; Lucile Sinck; Natalie J Ward; Carlos E Melendez-Peña; Robert J Scarborough; Ibrahim Azar; Elodie Rance; Aïcha Daher; Ka-Ming Pang; John J Rossi; Anne Gatignol
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

2.  Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.

Authors:  Sonia Guedan; Juan José Rojas; Alena Gros; Elena Mercade; Manel Cascallo; Ramon Alemany
Journal:  Mol Ther       Date:  2010-05-04       Impact factor: 11.454

3.  Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers.

Authors:  Cristina Puig-Saus; Alena Gros; Ramon Alemany; Manel Cascalló
Journal:  Mol Ther       Date:  2011-08-23       Impact factor: 11.454

4.  Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy.

Authors:  Jordi Martinez-Quintanilla; Derek He; Hiroaki Wakimoto; Ramon Alemany; Khalid Shah
Journal:  Mol Ther       Date:  2014-10-29       Impact factor: 11.454

5.  Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity.

Authors:  Matthew J Johnson; Constantinos Petrovas; Takuya Yamamoto; Ross W B Lindsay; Karin Loré; Jason G D Gall; Emma Gostick; François Lefebvre; Mark J Cameron; David A Price; Elias Haddad; Rafick-Pierre Sekaly; Robert A Seder; Richard A Koup
Journal:  J Immunol       Date:  2012-05-14       Impact factor: 5.422

Review 6.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15

7.  CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.

Authors:  Montserrat Puigdelloses; Marc Garcia-Moure; Sara Labiano; Virginia Laspidea; Marisol Gonzalez-Huarriz; Marta Zalacain; Lucia Marrodan; Naiara Martinez-Velez; Daniel De la Nava; Iker Ausejo; Sandra Hervás-Stubbs; Guillermo Herrador; ZhiHong Chen; Dolores Hambardzumyan; Ana Patino Garcia; Hong Jiang; Candelaria Gomez-Manzano; Juan Fueyo; Jaime Gállego Pérez-Larraya; Marta Alonso
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 12.469

8.  Therapeutic potential of replication-selective oncolytic adenoviruses on cells from familial and sporadic desmoid tumors.

Authors:  Inge Peerlinck; Saeid Amini-Nik; Robin K Phillips; Richard Iggo; Nicholas R Lemoine; Sabine Tejpar; Georges Vassaux
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

9.  RNAi suppressor P19 can be broadly exploited for enhanced adenovirus replication and microRNA knockdown experiments.

Authors:  Christina Rauschhuber; Martin Mueck-Haeusl; Wenli Zhang; Dirk M Nettelbeck; Anja Ehrhardt
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells.

Authors:  David Sharon; Michael Schümann; Sheena MacLeod; Robyn McPherson; Shyambabu Chaurasiya; Andrew Shaw; Mary M Hitt
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.